# A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject

> **NCT03278470** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** HL237
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03278470
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-03-19
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278470, "A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03278470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*